Antimicrobial activity against Streptococcus pneumoniae and Haemophilus influenzae collected globally between 2004 and 2008 as part of the Tigecycline Evaluation and Surveillance Trial

Diagnostic Microbiology and Infectious Disease

Volumn 67, Issue 1, 2010, Pages 78-86

  Darabi, Ali ^a   Hocquet, Didier ^b   Dowzicky, Michael J ^c  

^a WPAHS   (United States)

^b UNIVERSITY HOSPITAL OF BESANÇON   (France)

^c PFIZER INC   (United States)

Author keywords

Antimicrobial surveillance; Haemophilus influenzae; Resistance; Streptococcus pneumoniae; Tigecycline

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BETA LACTAMASE; CEFEPIME; CEFTRIAXONE; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MINOCYCLINE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; VANCOMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; ASIA; BACTERIUM ISOLATE; CONTROLLED STUDY; EUROPE; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORTH AMERICA; PACIFIC ISLANDS; PENICILLIN RESISTANCE; PRIORITY JOURNAL; SOUTH AFRICA; STREPTOCOCCUS PNEUMONIAE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ASIA; BACTERIAL PROTEINS; BETA-LACTAMASES; CHILD; CHILD, PRESCHOOL; EUROPE; FEMALE; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MINOCYCLINE; NORTH AMERICA; PENICILLIN RESISTANCE; PNEUMOCOCCAL INFECTIONS; SOUTH AFRICA; STREPTOCOCCUS PNEUMONIAE; YOUNG ADULT;

EID: 77951477729     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2009.12.009     Document Type: Article

References (42)

1. Adam D. Global antibiotic resistance in Streptococcus pneumoniae. J. Antimicrob. Chemother. 2002, 50:1-5.
2. Bergallo C., Jasovich A., Teglia O., Oliva M.E., Lentnek A., de Wouters L., Zlocoqski J.C., Dukart G., Cooper A., Mallick R. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn. Microbiol. Infect. Dis. 2009, 63:52-61.
3. Biedenbach D.J., Jones R.N. Five-year analysis of Haemophilus influenzae isolates with reduced susceptibility to fluoroquinolones: prevalence results from the SENTRY antimicrobial surveillance program. Diagn. Microbiol. Infect. Dis. 2003, 46:55-61.
4. Brown S.D., Traczewski M.M. Comparative in vitro antimicrobial activity of a new carbapenem, doripenem: tentative disc diffusion criteria and quality control. J. Antimicrob. Chemother. 2005, 55:944-949.
5. Casellas J.M., Bantar C., Duret F. Comparative in vitro activity of tigecycline against aerobic and facultative isolates recovered from hospitalized patients: an Argentinean multicentre study. J. Chemother. 2007, 19:482-487. Argentinean Collaborative Test Group.
6. Cerquetti M., Giufrè M., Cardines R., Mastrantonio P. First characterisation of heterogeneous resistance to imipenem in invasive nontypeable Haemophilus influenzae isolates. Antimicrob. Agents Chemother. 2007, 51:3155-3161.
7. Chiu C.H., Su L.H., Huang Y.C., Lai J.C., Chen H.L., Wu T.L., Lin T.Y. Increasing ceftriaxone resistance and multiple alterations of penicillin-binding proteins among penicillin-resistant Streptococcus pneumoniae in Taiwan. Antimicrob. Agents Chemother. 2007, 51:3404-3406.
8. Clinical and Laboratory Standards Institute (CLSI) Performance standard for antimicrobial susceptibility testing, document M100-S16 2006, CLSI, Wayne, PA.
9. Clinical and Laboratory Standards Institute (CLSI) Performance standard for antimicrobial susceptibility testing, document M100-S18 2008, CLSI, Wayne, PA.
10. Conte J.E., Golden J.A., Kelly M.G., Zurlinden E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int. J. Antimicrob. Agents 2005, 25:523-529.
11. Dean C.R., Visalli M.A., Projan S.J., Sum P.E., Bradford P.A. Efflux-Mediated Resistance to Tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob. Agents Chemother. 2003, 47:972-978.
12. Doern G.V., Richter S.S., Miller A., Miller N., Rice C., Heilmann K., Beekmann S. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes?. Clin. Infect. Dis. 2005, 41:139-148.
13. Draghi D.C., Tench S., Dowzicky M.J., Sahm D.F. Baseline in vitro activity of tigecycline among key bacterial pathogens exhibiting multidrug resistance. Chemotherapy 2008, 54:91-100.
14. Felmingham D., Canton R., Jenkins S.G. Regional trends in β-lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001-2004. J. Infect. 2007, 55:111-118.
15. Fritsche T.R., Sader H.S., Stilwell M.G., Dowzicky M.J., Jones R.N. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn. Microbiol. Infect. Dis. 2005, 52:187-193.
16. Gonullu N., Catal F., Kucukbasmaci O., Ozdemir S., Torun M.M., Berkiten R. Comparison of in vitro activities of tigecycline with other antimicrobial agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in two university hospitals in Istanbul, Turkey. Chemotheraphy 2009, 55:161-167.
17. Gür D., Gülay Z., Akan O.A., Aktaş Z., Kayacan C.B., Cakici O., Eraç B., Gültekin M., Oǧünç D., Söyletir G., Unal N., Uysal S. Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study. Mikrobiyol. Bul. 2008, 42:537-544.
18. Hoban D.J., Doern G.V., Fluit A.C., Roussel-Delvallez M., Jones R.N. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. 2001, 32:S81-S93.
19. Hoban D., Felmingham D. The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections. J. Antimicrob. Chemother. 2002, 50(Suppl S1):49-59.
20. Johnson D.M., Sader H.S., Fritsche T.R., Biedenbach D.J., Jones R.N. Susceptibility trends of Haemophilus influenzae and Moraxella catarrhalis against orally administered antimicrobial agents: five-year report from the SENTRY Antimicrobial Surveillance Program. Diagn. Microbiol. Infect. Dis. 2003, 47:373-376.
21. Kim I.S., Ki C.S., Kim S., Oh W.S., Peck K.R., Song J.H., Lee K., Lee N.Y. Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolates in Korea. Antimicrob. Agents Chemother. 2007, 51:453-460.
22. Ko K.S., Song J.H., Lee M.Y., Park S., Kwon K.T., Heo S.T., Ryu S.Y., Oh W.S., Peck K.R., Lee N.Y. Antimicrobial activity of tigecycline against recent isolates of respiratory pathogens from Asian countries. Diagn. Microbiol. Infect. Dis. 2006, 55:337-341.
23. Lau Y.J., Hsueh P.R., Liu Y.C., Shyr J.M., Huang W.K., Teng L.J., Liu C.Y., Luh K.T. Comparison of in vitro activities of tigecycline with other antimicrobial agents against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in Taiwan. Microb. Drug Resist. 2006, 12:130-135.
24. Mandell L.A., Wunderink R.G., Anzueto A., Bartlett J.G., Campbell G.D., Dean N.C., Dowell S.F., File T.M., Musher D.M., Niederman M.S., Torres A., Whitney C.G. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 2007, 44(Suppl 2):S27-S72.
25. Marchese A., Schito G.C. Recent findings from multinational resistance surveys: are we 'PROTEKTed' from resistance?. Int. J. Antimicrob. Agents 2007, 29(Suppl 1):S2-S5.
26. McKeage K., Keating G.M. Tigecycline: in community-acquired pneumonia. Drugs 2008, 68:2633-2644.
27. Miyazaki S., Fujikawa T., Kanazawa K., Yamaguchi K. In vitro and in vivo activities of meropenem and comparable antimicrobial agents against Haemophilus influenzae, including β-lactamase-negative ampicillin-resistant strains. J. Antimicrob. Chemother. 2001, 48:723-726.
28. Morrissey I., Maher K., Williams L., Shackcloth J., Felmingham D., Reynolds R. Non-susceptibility trends among Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections in the UK and Ireland, 1999-2007. J. Antimicrob. Chemother. 2008, 62(Suppl 2):ii97-ii103. on behalf of the BSAC Working Parties on Resistance Surveillance.
29. Paul M., Weinberger M., Siegman-Igra Y., Lazarovitch T., Ostfeld I., Boldur I., Samra Z., Shula H., Carmeli Y., Rubinovitch B., Pitlik S. Acinetobacter baumannii: emergence and spread in Israeli hospitals 1997-2002. J. Hosp. Infect. 2005, 60:256-260.
30. Peleg A.Y., Adams J., Paterson D.L. Tigecycline efflux as a mechanism for nonsusceptibility in Acinetobacter baumannii. Antimicrob. Agents Chemother. 2007, 51:2065-2069.
31. Reinert R.R. The antimicrobial resistance profile of Streptococcus pneumoniae. Clin. Microbiol. Infect. 2009, 15(Suppl 3):7-11.
32. Rello J. Demographics, guidelines, and clinical experience in severe community-acquired pneumonia. Crit. Care 2008, 12(Suppl 6):S2.
33. Richter S.S., Heilmann K.P., Dohrn C.L., Riahi F., Beekmann S.E., Doern G.V. Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004-2005. Clin. Infect. Dis. 2009, 48:e23-e33.
34. Sahm D.F., Brown N.P., Draghi D.C., Evangelista A.T., Cheung Yee Y., Thornsberry C. Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST surveillance initiative, 2001-2005. Postgrad. Med. 2008, 120(Suppl 3):8-15.
35. Sahm D.F., Brown N.P., Thornsberry C., Jones M.E. Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective. Postgrad. Med. 2008, 120(Suppl 3):16-24.
36. Sanbongi Y., Suzuki T., Osaki Y., Senju N., Ida T., Ubukata K. Molecular evolution of β-lactam resistant Haemophilus influenzae: 9-year surveillance of penicillin-binding protein 3 mutations in isolates from Japan. Antimicrob. Agents Chemother. 2006, 50:2487-2492.
37. Tanaseanu C., Bergallo C., Teglia O., Jasovich A., Oliva M.E., Dukart G., Dartois N., Cooper C.A., Gandjini H., Mallick R. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn. Microbiol. Infect. Dis. 2008, 61:329-338. 3008 Study Group, 313 Study Group.
38. Tristram S., Jacobs M.R., Appelbaum P.C. Antimicrobial resistance in Haemophilus influenzae. Clin. Microbiol. Rev. 2007, 20:368-389.
39. Tsao S.M., Lin H.C., Lee C.M., Hsu G.J., Chen C.M., Sun W., Liu Y.C., Jang T.N., Cheng Y.J., Lu P.L., Chiang P.C., Wang L.S., Kung H.C., Chuang Y.C., Shi Z.Y., Liu J.W., Huang C.H., Lu C.T., Liao C.H., Hsueh P.R. Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of Gram-positive cocci. Int. J. Antimicrob. Agents 2008, 32(Suppl 3):S184-S187.
40. Visalli M.A., Murphy E., Projan S.J., Bradford P.A. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob. Agents Chemother. 2003, 47:665-669.
41. Wimmerstedt A., Kahlmeter G. Associated antimicrobial resistance in Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae and Streptococcus pyogenes. Clin. Microbiol. Infect. 2008, 14:315-321.
42. Wyeth Pharmaceuticals Inc Tygacil prescribing information. Philadelphia, PA, USA (Last accessed 7 May 2009). http://www.tygacil.com.